Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.

In this study, Astragaloside IV was found to inhibit apoptosis-related pathways in hair follicles of mice, suggesting it may serve as an alternative therapy for hair loss.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This study suggests that stimulating olfactory receptors in human hair follicles with Sandalore® increases antimicrobial activity by upregulating dermcidin production, potentially offering a novel approach for treating hair follicle diseases with bacterial issues.

In this case study, a young female with aseptic and alopecic nodules of the scalp achieved full resolution without recurrence using intralesional steroids.

This study found that betamethasone valerate foam was more effective and well-tolerated than betamethasone dipropionate lotion in treating mild-to-moderate alopecia areata, with higher hair regrowth rates observed.

This review reports that sonidegib and vismodegib, two Hedgehog inhibitors used for treating advanced basal cell carcinoma, have similar efficacy and safety profiles, but differ in pharmacokinetics, with sonidegib achieving peak concentration more rapidly and reaching steady state later than vismodegib.

In this study, a shampoo and hair tonic containing the botanical extract blend Asacurin100 reduced hair loss and improved scalp health in 35 male participants with androgenetic alopecia, without serious side effects, suggesting potential efficacy that warrants larger trials for confirmation.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

This report describes a case where a 44-year-old male treated with vorasidenib for diffuse low-grade gliomas developed unexpected hair growth, including in areas of severe hair loss, after one month, highlighting a previously undocumented side effect.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

Clascoterone safely promotes hair growth similar to minoxidil.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

This study found that Yangxuebushen Decoction significantly promoted hair regrowth and improved hair follicle structure in a cyclophosphamide-induced alopecia mouse model by reducing inflammation, oxidative stress, and apoptosis.

This case report suggests that exacerbations of alopecia areata in a 40-year-old woman may be associated with sodium tetradecyl sulphate foam sclerotherapy treatments for varicose veins.

This study suggests that macrophages, especially CD206+ subsets, play a key role in hair growth induced by squaric acid dibutyl ester, a therapy used for alopecia areata.

This report describes two cases where topical squaric acid dibutylester application in alopecia totalis patients led to severe pustular lesions, necessitating systemic prednisolone treatment.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This review discusses the impact of sarcoptic mange on wombats and evaluates antiparasitic drugs like ivermectin, moxidectin, and fluralaner for treating the disease, but it presents no new clinical results.

This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

In this clinical study, researchers reported that both sodium valproate-loaded nanospanlastics and topical corticosteroids showed comparable modest efficacy in treating patchy alopecia areata, recommending further investigation into sodium valproate's role combined with other therapies.

This case report describes a unique instance of a 6-year-old girl developing angioedema after treatment with squaric acid dibutylester for alopecia areata.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

This study investigated a new formula called SV-loaded nanospanlastics for topical application to treat androgenic alopecia. It showed similar effectiveness to minoxidil lotion but with fewer adverse effects when used to enhance dermal delivery and efficacy of sodium valproate.